Lipocine Resubmits NDA for Its Oral Testosterone Product Candidate, LPCN 1021, for Treatment of Hypogonadism

SALT LAKE CITY, Aug. 09, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced the resubmission of a New Drug Application ( " NDA " ) for LPCN 1021, its oral testosterone product candidate for...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news